acquired
Stage
2014
Founded
3
Investors
About
Versantis is a clinical-stage biotech company developing novel drug therapies to treat liver, pediatric, and rare diseases using a proprietary detoxification platform. Its lead candidate VS-01 targets acute-on-chronic liver failure, and the company was acquired by Genfit in 2022.
Explore Versantis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.